ESLA

SEC source: 0001996255-26-000004 · primary_doc.xml · derivative · entry 2

Liu Cheng · CIK 0001996255 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 900,000

Underlying: Common Stock · 100,000 shares

Expires 2034-10-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Represents incentive share options granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan, of which twenty-five percent (25%) was immediately exercisable on the date of grant, with the remainder vesting in equal monthly installments of 1/48th of the total award on each monthly anniversary of October 30, 2024. The options were vested as to the shares exercised.

F4 · price: Not applicable. The reported transaction is the exercise of the stock option for the exercise price set forth in Column 2. No separate consideration was paid or received for the derivative security.

F3 · derivative.exercise_date: Represents incentive share options granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan, of which twenty-five percent (25%) was immediately exercisable on the date of grant, with the remainder vesting in equal monthly installments of 1/48th of the total award on each monthly anniversary of October 30, 2024. The options were vested as to the shares exercised.

SEC source: 0001996255-26-000004 · primary_doc.xml · nonDerivative · entry 1

Liu Cheng · CIK 0001996255 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 397,437

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents the exercise price per share paid by the Reporting Person upon the exercise of the stock options reported in Table II.

F2 · balance_after: Reflects the 297,437 shares of Common Stock directly beneficially owned as reported on the Reporting Person's most recent Form 4, plus the 100,000 shares acquired upon the reported exercise.

SEC source: 0001213900-26-093698 · ownership.xml · derivative · entry 2

Xu Jiandong · CIK 0001920399 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 390,796

Underlying: Common Stock · 100,000 shares

Expires 2034-10-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Represents incentive share options granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan, of which twenty-five percent (25%) was immediately exercisable on the date of grant, with the remainder vesting in equal monthly installments of 1/48th of the total award on each monthly anniversary of October 30, 2024. The options were vested as to the shares exercised.

F4 · price: Not applicable - the reported transaction is the exercise of the stock option for the exercise price set forth in Column 2; no separate consideration was paid or received for the derivative security.

F3 · derivative.exercise_date: Represents incentive share options granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan, of which twenty-five percent (25%) was immediately exercisable on the date of grant, with the remainder vesting in equal monthly installments of 1/48th of the total award on each monthly anniversary of October 30, 2024. The options were vested as to the shares exercised.

SEC source: 0001213900-26-093698 · ownership.xml · nonDerivative · entry 1

Xu Jiandong · CIK 0001920399 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 365,488

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents the exercise price per share paid by the Reporting Person upon the exercise of the stock options reported in Table II.

F2 · balance_after: Reflects the 265,488 shares of Common Stock directly beneficially owned as reported on the Reporting Person's most recent Form 4, plus the 100,000 shares acquired upon the reported exercise.

SEC source: 0001213900-26-049602 · ownership.xml · nonDerivative · entry 3

Xu Jiandong · CIK 0001920399 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 265,488

SEC source: 0001213900-26-049602 · ownership.xml · nonDerivative · entry 2

Xu Jiandong · CIK 0001920399 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 16,700

F1 · balance_after: Held by the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F1 · ownership.nature: Held by the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

SEC source: 0001213900-26-049602 · ownership.xml · nonDerivative · entry 1

Xu Jiandong · CIK 0001920399 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 264,588

SEC source: 0001213900-25-014306 · ownership.xml · derivative · entry 2

Xu Jiandong · CIK 0001920399 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 509,203

Underlying: Common Stock · 509,204 shares

Expires 2034-10-29

F2 · kind: The incentive share options will vest on a schedule, with twenty-five percent (25%) of the award being immediately exercisable on the date of the grant, with the remaining seventy-five percent (75%) vesting in equal monthly installments over the subsequent thirty-six (36) months. Each subsequent monthly vesting will represent a total of 1/48 of the total award, with 1/48th of the total number of shares subject to the option vesting on each monthly anniversary of October 30, 2024.

F2 · price: The incentive share options will vest on a schedule, with twenty-five percent (25%) of the award being immediately exercisable on the date of the grant, with the remaining seventy-five percent (75%) vesting in equal monthly installments over the subsequent thirty-six (36) months. Each subsequent monthly vesting will represent a total of 1/48 of the total award, with 1/48th of the total number of shares subject to the option vesting on each monthly anniversary of October 30, 2024.

F4 · derivative.exercise_date: The nonstatutory share options will vest on a schedule, with twenty-five percent (25%) of the award being immediately exercisable on the date of the grant, with the remaining seventy-five percent (75%) vesting in equal monthly installments over the subsequent thirty-six (36) months, with 1/48th of the total number of shares subject to the option vesting on each monthly anniversary of October 30, 2024.

SEC source: 0001213900-25-014306 · ownership.xml · derivative · entry 1

Xu Jiandong · CIK 0001920399 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 490,796

Underlying: Common Stock · 490,796 shares

Expires 2034-10-29

F1 · kind: On October 30, 2024, the Board of Directors (the "Board") of Estrella Immunopharma, Inc. (the "Company"), awarded Mr. Jiangdong "Peter" Xu an incentive share option grant of 490,796 shares.

F1 · price: On October 30, 2024, the Board of Directors (the "Board") of Estrella Immunopharma, Inc. (the "Company"), awarded Mr. Jiangdong "Peter" Xu an incentive share option grant of 490,796 shares.

F3 · derivative.exercise_date: On October 31, 2024, the Board of the Company awarded Mr. Xu a nonstatutory shares option grant of 509,204 shares.

SEC source: 0001213900-25-014310 · ownership.xml · derivative · entry 2

Liu Cheng · CIK 0001996255 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 509,203

Underlying: Common Stock · 509,204 shares

Expires 2034-10-29

F2 · kind: The incentive share options will vest on a schedule, with twenty-five percent (25%) of the award being immediately exercisable on the date of the grant, with the remaining seventy-five percent (75%) vesting in equal monthly installments over the subsequent thirty-six (36) months, with 1/48th of the total number of shares subject to the option vesting on each monthly anniversary of October 30, 2024.

F2 · price: The incentive share options will vest on a schedule, with twenty-five percent (25%) of the award being immediately exercisable on the date of the grant, with the remaining seventy-five percent (75%) vesting in equal monthly installments over the subsequent thirty-six (36) months, with 1/48th of the total number of shares subject to the option vesting on each monthly anniversary of October 30, 2024.

F4 · derivative.exercise_date: The nonstatutory share options will vest on a schedule, with twenty-five percent (25%) of the award being immediately exercisable on the date of the grant, with the remaining seventy-five percent (75%) vesting in equal monthly installments over the subsequent thirty-six (36) months, with 1/48th of the total number of shares subject to the option vesting on each monthly anniversary of October 30, 2024.

SEC source: 0001213900-25-014310 · ownership.xml · derivative · entry 1

Liu Cheng · CIK 0001996255 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 490,796

Underlying: Common Stock · 490,796 shares

Expires 2034-10-29

F1 · kind: On October 30, 2024, the Board of Directors (the "Board") of Estrella Immunopharma, Inc. (the "Company"), awarded Mr. Cheng Liu an incentive share option grant of 490,796 shares.

F1 · price: On October 30, 2024, the Board of Directors (the "Board") of Estrella Immunopharma, Inc. (the "Company"), awarded Mr. Cheng Liu an incentive share option grant of 490,796 shares.

F3 · derivative.exercise_date: On October 30, 2024, the Board of the Company awarded Mr. Liu a nonstatutory shares option grant of 509,204 shares.

SEC source: 0000902664-23-005013 · ownership.xml · nonDerivative · entry 1

Owl Creek Asset Management, L.P. · CIK 0001313756 · 10% owner

ALTMAN JEFFREY A · CIK 0001269751 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · kind: In connection with the closing of the Issuer's business combination, the shares held by OCCOMF (as defined below) were redeemed.

F2 · ownership.nature: The securities to which this filing relates are held directly by Owl Creek Credit Opportunities Master Fund, L.P., a Cayman Islands exempted limited partnership ("OCCOMF"), to which Owl Creek Asset Management, L.P., a Delaware limited partnership (the "Investment Manager"), serves as investment manager. Jeffrey A. Altman ("Mr. Altman") is the managing member of the general partner of the Investment Manager. Each of the Investment Manager and Mr. Altman disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0001104659-22-035068 · tm229530-1_4seq1.xml · nonDerivative · entry 1

Li Jianwei · CIK 0001858469 · Director · Co-Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,253,730

F1 · balance_after: Mr. Jianwei Li beneficially owns 141,970 shares of Common Stock directly and may be deemed to beneficially own 1,111,760 shares of Common Stock held by TradeUP Acquisition Sponsor LLC (the "Sponsor"). As a result, Mr. Jianwei Li in aggregate beneficially owns 1,253,730 shares of Common Stock.

F2 · balance_after: Mr. Jianwei Li is the manager of the Sponsor. As such Mr. Li may be deemed to have beneficial ownership of the shares of Common Stock held directly by the Sponsor. Mr. Li disclaims beneficial ownership over any securities owned by the Sponsor in which he does not have any pecuniary interest.